The link you have chosen leads to a site maintained by a third party over whom Bracco has no control.

As such, Bracco makes no representation as to the accuracy or any other aspect of the information on this site.

Do you want to continue?

OK

Cancel

The Group

Bracco is an international Group active in the healthcare sector and a leader in diagnostic imaging. It has around 3,420 employees and annual total consolidated revenues of around 1,29 billion euros, 86% of which from international sales. In the Research and Development area, the company invests approximately 9% of reference turnover in the imaging diagnostics and medical devices sectors and has a portfolio comprising over 2,000 patents.

Product portfolio

The Group’s main products are contrast agents, medical substances used to improve the diagnostic accuracy of biomedical imaging and the care of patients affected by diseases of varying type and severity. Contrast agents are routinely and widely used in all diagnostic imaging modalities, such as radiographic procedures, including computed tomography (CT), magnetic resonance imaging (MRI), ultrasound and nuclear medicine.

Global commercial presence

Bracco contrast media are sold in over 100 countries, both directly and indirectly through branches, joint ventures and licence and distribution agreements. Thanks to the quality and reliability of its products, the Group boasts leading positions in the most important geographical areas such as North America, China, Europe and Japan.

Research and Innovation in DNA

Research and Development activities are concentrated in the laboratories in Geneva and Lausanne (Switzerland), Monroe and Silicon Valley (United States) and Colleretto Giacosa (Italy). Each research centre has specialised experience and expertise at the absolute cutting edge in different imaging modalities and operates in synergy with the medical and regulatory departments, whose operations are located in Milan (Italy), Konstanz (Germany), Paris (France), Monroe and Long Island (United States), Montreal (Canada), Mexico City (Mexico), São Paulo (Brazil), Beijing (China), and Tokyo (Japan).

Thanks to constant investment in operating processes, Bracco Imaging has reached levels of excellence in quality, in full compliance with all applicable regulations in every country where it operates, and with special attention paid to ecologically sustainable production.

The production activities of Bracco Imaging are carried out in Italy (Ceriano Laghetto, Torviscosa and Colleretto Giacosa), Canada (Montreal), Switzerland (Geneva), Germany (Singen), Japan (Saitama) and China (Shanghai).

The Bracco diagnostic imaging product portfolio is completed by medical devices and advanced imaging agents injection systems (Acist and Bracco Injeneering).

Another important area of activity of the Bracco Group regards the healthcare services provided by the Centro Diagnostico Italiano, a polyclinic based in Milan.

Since its foundation, Bracco has been a socially responsible company in each area of activity - in business as in every other context. The company is strongly committed to social, educational, environmental and cultural improvement and in the promotion of Gender Equality.